Sanofi-Queensland Government partnership paves way for highly-skilled medical research roles

Pharma News: The $280 million Translational Science Hub, a partnership announced in December by Sanofi and the Queensland Government, is utilising the laboratories and infrastructure at the University of Queensland and Griffith University.

Sanofi has opened the first wave of senior medical research career opportunities available at the Translational Science Hub in Queensland.

The Translational Science Hub will initially focus on the evaluation of a new generation of mRNA vaccines and the development of mRNA immunisations, including a world-first mRNA vaccine for chlamydia.

Dr Steven Miles MP, Queensland Deputy Premier, said “The Translational Science Hub is set to create up to 200 jobs and deliver long-term benefits for local manufacturing, the biomedical supply chain, and the health of Queenslanders. It’s an attractive offering for medical research specialists, to be linked with global experts and to put your mark on home-grown research and innovation.”

Sanofi is on the look-out for a Brisbane-based Director of Clinical Operations, a Global Clinical Development Strategic Lead, Global Study Managers, a Strategic Partnerships Lead and a Project Coordinator.

Dr Iris Depaz, Country Medical Lead, Sanofi ANZ, stated “We are offering Global positions located in Queensland. The people we hire will have regular contact with Sanofi scientists in France and the US, while also working with our university partners in Queensland to develop the next generation of vaccines. This collaboration and knowledge sharing will accelerate the development of vaccine technology that has the potential to improve public health.

“These newly opened positions are truly special career opportunities for qualified people wanting to be part of a global research network while living in Queensland.”

Chlamydia is the most common sexually transmitted infection (STI) in the world, and the most reported among young people in Australia. In 2021, there were 22,000 reported cases of chlamydia in Queensland, and some 129 million infections reported worldwide in 2020.

While chlamydia can be treated, there is currently no vaccine to prevent infection. If left untreated it can lead to infertility and in pregnant women can result in foetal eye and lung infections.

The importance of investigating chlamydia vaccine candidates has obvious potential social and economic benefits locally, but the real benefits will likely be seen in low- and middle-income countries where accurate diagnostic testing is largely unavailable.

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.